EMEA-002333-PIP02-19
Key facts
| Active substance |
2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl](methyl)amino]-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile
|
| Therapeutic area |
Pneumology-allergology
|
| Decision number |
P/0148/2020
|
| PIP number |
EMEA-002333-PIP02-19
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of interstitial pulmonary diseases with fibrosis
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Galapagos NV
Tel. ++32 15342900 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|